Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: pertuzumab [Perjeta]|DRUG: trastuzumab [Herceptin]
Sponsor: Hoffmann-La Roche